Podcast: How will biotech and biopharma manage with more funding cuts?
The biotech and biopharma industry has struggled in recent years with a lack of investment. While GlobalData has tracked an …
Post
-
-
Innovent Biologics doses first subject in trial of ovarian cancer therapy
Innovent Biologics has dosed the first subject in the randomised Phase III HeriCare-Ovarian01 trial of IBI354 for treating platinum-resistant ovarian …
-
Rising Sirturo resistance highlights urgent need for new TB therapies
There have been widespread reports that more effort and funding is needed to combat the TB crisis. As more cases …
-
Elypta’s urine test identifies 90% of recurrent kidney cancer cases
Swedish cancer diagnostic company Elypta’s urine test has been able to accurately identify 90% of patients with recurrent kidney cancer. The …
-
Omeros to activate site for Phase III programme of zaltenibart for PNH
Omeros has announced that the activation of clinical trial sites for patient enrolment is now in progress for its Phase …
-
Omeros to activate site for Phase III programme of zaltenibart for PNH
Omeros has announced that the activation of clinical trial sites for patient enrolment is now in progress for its Phase …
-
First subject enrolled in MUSC Hollings’ Phase II/III trial of HNSCC treatment
The Medical University of South Carolina (MUSC) Hollings Cancer Center, US, has enrolled the first subject in the Phase II/III FORTIFI-NH01 …
-
MacroGenics axes ADC drug following Phase II failure in prostate cancer
MacroGenics is axing the development of one of its antibody-drug conjugates (ADC) after it flopped in a Phase II study …
-
iECURE gene therapy data suggests partial restoration of functional OTC
Gene editing company iECURE has said data from its Phase I/II ornithine transcarbamylase (OTC) deficiency trial could suggest partial restoration …
-
Mastering compliance and copyright in healthcare and MedComms
In a recent webinar, Marc McArdle, CLA Customer Success Manager, was joined by Jackie Marchington, Head of Compliance and Ethics …
-
Icon integrates Medidata’s Clinical Data Studio into clinical studies
Clinical research organisation (CRO) Icon has begun the integration of Medidata Clinical Data Studio into its clinical studies. This development makes …
-
Mixed data results for two Monte Rosa molecular glue degraders
Monte Rosa Therapeutics has seen good news for one of its molecular glue degradation candidates and bad news for another …
-
Global funding cuts reversing decades of tuberculosis progress, WHO says
Ahead of World Tuberculosis Day on 24 March, the World Health Organization (WHO) has said that cuts in global funding …
-
IGC adds new clinical site in Canada for Alzheimer’s agitation therapy trial
IGC Pharma has added Hamilton Health Sciences (HHS) in Canada as a new clinical site for its ongoing, randomised Phase …
-
Potential impacts of the US withdrawal from the WHO on clinical trials globally
The US is set to sever its relationship with the World Health Organization (WHO) as President Donald Trump has issued …
